Investors

Oncopeptides strives to ensure that analysts, investors, shareholders and financial media are provided with correct information to enhance understanding of our operations.

Nasdaq Stockholm

Price

Change

Latest investor news

June 10, 2026

Sofia Heigis presented at Aktiespararna

Investor

May 15, 2026

Oncopeptalks: Q1 report

Investor

May 13, 2026

Redeye interviews Oncopeptides CEO Sofia Heigis

Investor

May 8, 2026

Launching: Oncopeptalks as a podcast

Investor

March 23, 2026

CEO Sofia Heigis presented at Redeye event Commercialization in Life Science

Investor

March 20, 2026

Sofia Heigis presented and interviewed at Stockholm Corporate Finance Life Science Days

Investor

March 11, 2026

CEO Sofia Heigis presents Oncopeptides at Aktiespararna

Investor

March 5, 2026

Biostock: presentation and interview with Sofia Heigis

Investor

June 17, 2026

First patient enrolled in Oncopeptides’ glioblastoma study

Science

June 12, 2026

Oncopeptides submits Type II variation application to EMA for Pepaxti label expansion into third line treatment

June 8, 2026

First patient enrolled in Oncopeptides’ real-world evidence study MARINA in Germany

May 27, 2026

Oncopeptides to present clinical and translational data on Pepaxti at EHA 2026 in Stockholm

No upcoming events

Investor Relations Contact

David Augustsson, MSc

Director of IR and Communications

ir@oncopeptides.com

+46 762 29 38 68

Investors

Latest investor news

Investor Relations Contact

More investor information

The share

General Meeting

Financial Reports

Financial Calendar